Genetic research progress in branchio-oto syndrome/ branchio-oto-renal syndrome.
10.11817/j.issn.1672-7347.2022.210251
- Author:
Anhai CHEN
1
;
Jie LING
2
;
Yong FENG
3
Author Information
1. Department of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008. 198101041@csu.edu.cn.
2. Medical Functional Experiment Center, School of Basic Medicine, Central South University, Changsha 410078.
3. Department of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008. fengyong_hn@hotmail.com.
- Publication Type:Journal Article
- Keywords:
EYA1 gene;
SIX1 gene;
SIX5 gene;
branchio-oto syndrome;
branchio-oto-renal syndrome;
hearing disorder
- MeSH:
Branchio-Oto-Renal Syndrome/pathology*;
Chromosome Deletion;
Comparative Genomic Hybridization;
Genetic Research;
Homeodomain Proteins/genetics*;
Humans;
Intracellular Signaling Peptides and Proteins;
Nuclear Proteins/metabolism*;
Pedigree;
Protein Tyrosine Phosphatases/metabolism*
- From:
Journal of Central South University(Medical Sciences)
2022;47(1):129-138
- CountryChina
- Language:English
-
Abstract:
Branchio-oto syndrome (BOS)/branchio-oto-renal syndrome (BORS) is a kind of autosomal dominant heterogeneous disorder. These diseases are mainly characterized by hearing impairment and abnormal phenotype of ears, accompanied by renal malformation and branchial cleft anomalies including cyst or fistula, with an incidence of 1/40 000 in human population. Otic anormalies are one of the most obvious clinical manifestations of BOS/BORS, including deformities of external, middle, inner ears and hearing loss with conductive, sensorineural or mix, ranging from mild to profound loss. Temporal bone imaging could assist in the diagnosis of middle ear and inner ear malformations for clinicians. Multiple methods including direct sequencing combined with next generation sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA), or array-based comparative genomic hybridization (aCGH) can effectively screen and identify pathogenic genes and/or variation types of BOS/BORS. About 40% of patients with BOS/BORS carry aberrations of EYA1 gene which is the most important cause of BOS/BORS. A total of 240 kinds of pathogenic variations of EYA1 have been reported in different populations so far, including frameshift, nonsense, missense, aberrant splicing, deletion and complex rearrangements. Human Endogenous Retroviral sequences (HERVs) may play an important role in mediating EYA1 chromosomal fragment deletion mutations caused by non-allelic homologous recombination. EYA1 encodes a phosphatase-transactivator cooperated with transcription factors of SIX1, participates in cranial sensory neurogenesis and development of branchial arch-derived organs, then regulates the morphological and functional differentiation of the outer ear, middle ear and inner ear toward normal tissues. In addition, pathogenic mutations of SIX1 and SIX5 genes can also cause BOS/BORS. Variations of these genes mentioned above may cause disease by destroying the bindings between SIX1-EYA1, SIX5-EYA1 or SIX1-DNA. However, the role of SIX5 gene in the pathogenesis of BORS needs further verification.
